This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Global Phasing Limited | |
|---|---|
| Name | Global Phasing Limited |
| Type | Private |
| Industry | Scientific software |
| Founded | 1997 |
| Founders | Ronald M. Glyde; Zbyszek Otwinowski |
| Headquarters | Cambridge, England |
| Key people | Paul Emsley; George Sheldrick |
| Products | Phaser; CCP4 suite integrations; Phenix interoperability |
| Num employees | 25–50 |
Global Phasing Limited is a United Kingdom–based company specializing in macromolecular crystallography software and services. It is principally known for developing the Phaser crystallographic phasing program and for providing commercial support, distribution, and maintenance for software used in structural biology. The company operates at the intersection of academic research groups and commercial biotechnology firms, interacting with institutions such as University of Cambridge, MRC Laboratory of Molecular Biology, European Molecular Biology Laboratory, and industrial actors including GlaxoSmithKline, Pfizer, and AstraZeneca.
Global Phasing Limited was founded in 1997 by researchers with roots at University of Cambridge and collaborators from Lawrence Berkeley National Laboratory and Diamond Light Source. Early work built on algorithms pioneered in academic settings such as the Molecular Replacement methods advanced at MRC Laboratory of Molecular Biology and statistical approaches from groups associated with Joint Centre for Structural Genomics projects. The company gained prominence through the release of Phaser, which implemented likelihood-based molecular replacement following theoretical frameworks developed by researchers connected to CCP4 initiatives and the Collaborative Computational Project Number 4 community. Throughout the 2000s Global Phasing expanded collaborations with structural genomics consortia including Protein Data Bank depositors, aligning with policy shifts at organizations like Wellcome Trust and European Commission funding programs. Key personnel movements linked the firm with prominent academics from University of Oxford, Imperial College London, and Max Planck Institute laboratories.
Global Phasing's flagship software, Phaser, is a program for molecular replacement and experimental phasing that integrates algorithms derived from statistical likelihood theory and Bayesian inference developed in academic literature associated with George Sheldrick and contemporaries at Harvard University and University of California, Berkeley. Phaser supports workflows compatible with suites and systems such as CCP4, Phenix, and tools used at synchrotron facilities like Diamond Light Source and European Synchrotron Radiation Facility. The company also provides GUI front-ends and binary distributions tailored for platforms used in laboratories at Stanford University, Massachusetts Institute of Technology, and ETH Zurich. Technology offerings emphasize cross-compatibility with file formats originating from Protein Data Bank depositions and with refinement engines inspired by methods from REFMAC and BUSTER development teams. Global Phasing’s software stack incorporates optimization routines, fast Fourier transform implementations, and scripting interfaces used by groups at European Molecular Biology Laboratory and biotech firms such as Genentech.
Global Phasing products are applied in structural determination projects spanning academic, industrial, and governmental research at organizations including Scripps Research Institute, The Sanger Institute, and National Institutes of Health. Pharmaceutical partnerships have involved structure-based drug-design efforts at Novartis and Roche; agricultural biotechnology collaborations have linked to research groups at John Innes Centre. The company has engaged in training and outreach with facilities like Diamond Light Source and Brookhaven National Laboratory, and has supported pipeline efforts in consortia such as Structural Genomics Consortium and initiatives coordinated by the Wellcome Trust. In the protein engineering and cryo-electron microscopy communities, interoperability with software from RELION developers and integration into pipelines used at Rutherford Appleton Laboratory have been highlighted. Commercial service agreements and licensing arrangements extended to contract research organizations serving clients including Biogen and Eli Lilly.
Global Phasing holds proprietary binaries and licensing models for distributing Phaser and associated utilities while maintaining academic source-code collaborations with projects such as CCP4 and Phenix. The company’s licensing mixes academic research-use permissions with commercial licenses sold to biotechnology and pharmaceutical firms like AstraZeneca and GlaxoSmithKline. Patent portfolios are limited compared with large multinational corporations, but the company asserts copyright and trademark protections over packaged distributions and graphical user interfaces; this approach has parallels with licensing practices at software vendors in structural biology including entities tied to Schrödinger, LLC and developers of CCP4 components. Interoperability agreements have been established with infrastructure providers at Diamond Light Source and with database curators at Protein Data Bank to ensure compliant use of deposited coordinates and reflection data.
Global Phasing operates as a privately held limited company based in Cambridge, England, with a compact team combining software engineers, crystallographers, and business development staff. Funding has come from consultancy revenue, commercial licensing, and collaborative grant-funded projects aligning with programs administered by bodies such as the Wellcome Trust, European Research Council, and national research councils in the United Kingdom. The company has contracted with academic laboratories at University of Cambridge and MRC Laboratory of Molecular Biology and has undertaken fee-for-service work for multinational firms like Pfizer and Novartis. Leadership draws on individuals who have published in journals affiliated with Nature Publishing Group and Oxford University Press outlets in structural biology.
Criticism of Global Phasing has largely centered on licensing and access tensions between proprietary distributions and open-source expectations voiced by communities around CCP4, Phenix, and the Protein Data Bank. Some academic users and consortia such as the Structural Genomics Consortium have argued for broader open-source availability to maximize reproducibility, echoing debates seen with other vendors tied to Schrödinger, LLC and commercial crystallography tools. Questions have also been raised about commercial support models in the context of public-funded research programs administered by bodies like the Wellcome Trust and European Commission, prompting discussions about sustainability and access similar to controversies involving software stewardship at repositories like GitHub and academic infrastructure hosted by European Molecular Biology Laboratory. Despite these debates, Global Phasing continues to be used in high-profile structural determinations and maintains collaborations across both academic and industrial sectors.
Category:Companies based in Cambridge Category:Crystallography software companies